

1 **Title page information:**

2  
3 **Title: Ventilation rates achieved in eucapnic voluntary hyperpnea challenge and**  
4  
5 **exercise-induced bronchoconstriction diagnosis in young patients with asthma**  
6

7  
8 José Ângelo Rizzo<sup>1,2</sup>; Laienne Carla Barbosa de Barros Albuquerque<sup>2,3</sup>; Décio Medeiros<sup>1,2</sup>;  
9  
10 Claudio Gonsalves de Albuquerque<sup>1,2</sup>; Edil de Albuquerque Rodrigues Filho<sup>1,2</sup>; Marcos André  
11  
12 de Moura Santos<sup>3,4</sup>; Steve Hunter<sup>5</sup>; Nadia Gaua<sup>5</sup>; Marco Aurélio de Valois Correia Junior,  
13  
14 PhD<sup>2,3,4</sup> \*  
15

16  
17  
18 <sup>1</sup>Postgraduate Program in Child and Adolescent Health, Universidade Federal de  
19  
20 Pernambuco, Recife, Brazil;

21  
22  
23 <sup>2</sup> Pneumology Department (Head). Center for Research in Allergy and Clinical Immunology,  
24  
25 Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Brazil;

26  
27  
28 <sup>3</sup>Postgraduate Program in Hebiatrics, Universidade de Pernambuco, Recife, Brazil;

29  
30  
31 <sup>4</sup>Associated Postgraduate Program in Physical Education, Universidade de Pernambuco and  
32  
33 Universidade Federal da Paraiba, Recife, Brazil ;

34  
35  
36 <sup>5</sup>Sport and Exercise Science Research Centre, School of Applied Sciences, London South  
37  
38 Bank University, London, United Kingdom.

39  
40  
41 **\*Corresponding author:** Marco Aurélio de Valois Correia Junior

42  
43 Rua Luiz Guimarães, 411, apto 301-a, CEP – 52061-160,

44  
45 Poço da Panela, Recife-PE. ORCID ID: 0000-0003-0386-5256

46  
47 Telephone: 55-81-992520056; E-mail: [marcovalois@gmail.com](mailto:marcovalois@gmail.com)  
48  
49

50 **Word count:**

51  
52 Manuscript =2600

53  
54 Abstract = 249

55  
56 number of tables = 2

57  
58 number of figures= 2  
59  
60  
61  
62  
63  
64  
65

## 26 Abstract

1  
2  
3 27 **Purpose:** Exercise-induced bronchoconstriction (EIB) affects approximately 50% of young  
4  
5 28 asthma patients, impairing their participation in sports and physical activities. Eucapnic  
6  
7  
8 29 voluntary hyperpnea (EVH) is an approved surrogate challenge to exercise for objective EIB  
9  
10 30 diagnosis, but the required minimum target hyperventilation rates remain unexplored in this  
11  
12  
13 31 population. This study aimed to evaluate the association between the achieved ventilation  
14  
15 32 rates (VRs) during a challenge and EIB-compatible response (EIB-cr) in young asthma  
16  
17  
18 33 patients. **Methods:** This cross-sectional study included 72 asthma patients aged 10–20 years.  
19  
20 34 Forced expiratory volume in the first second (FEV1) was measured before and 5, 15, and 30  
21  
22 35 min after the EVH. The target VR was set at 21 times the individual's baseline FEV1. A  
23  
24  
25 36 decrease of >10% in FEV1 after the challenge was considered an EIB-cr. The challenge was  
26  
27 37 repeated after 48–72h in those without an EIB-cr. **Results:** Thirty-six individuals had an EIB-  
28  
29  
30 38 cr at initial evaluation. The median VRs achieved was not different between individuals with  
31  
32 39 and without an EIB-cr (19.8 versus 17.9;  $p=0.619$ ). The proportion of individuals with an  
33  
34  
35 40 EIB-cr was nor different comparing those who achieved (12/25) or not (24/47) the calculated  
36  
37 41 target VRs ( $p=0.804$ ). At the repeated EVH challenge an EIB-cr was observed in 14/36  
38  
39  
40 42 individuals with a negative response in the first evaluation, with no differences in achieved  
41  
42 43 VRs between the two tests ( $p=0.463$ ). Conclusion: Irrespective of the achieved VR, an EIB  
43  
44 44 compatible response after an EVH challenge must be considered relevant for clinical and  
45  
46  
47 45 therapeutic judgment, and negative tests should be repeated.

48  
49  
50 46 **Keywords:** Exercise-induced bronchoconstriction, Lung function, Asthma, Eucapnic  
51  
52 47 voluntary hyperpnea.  
53  
54  
55  
56 48

## 49 Introduction

1  
2 50 Approximately 33–59% of asthma patients report exercise-associated respiratory  
3  
4 51 symptoms[1]. These symptoms may restrict their participation in salutary peer group physical  
5  
6  
7 52 activities, sports, and games[2–4]. Exercise-induced bronchoconstriction (EIB) is the most  
8  
9 53 common, although not the only cause of these symptoms[5,6], and affects approximately 50%  
10  
11 54 of young asthma patients[5], 10% of youngsters without asthma[6], and a significant  
12  
13  
14 55 proportion of competitive athletes[7]. EIB is defined as acute narrowing of the lower  
15  
16  
17 56 respiratory airways after exercise[5]. Correct EIB diagnosis is important to ensure  
18  
19 57 effectiveness of the treatment and to overcome the limitations of participation in sports and  
20  
21  
22 58 physical activities or playing, thereby promoting a healthy lifestyle[8].  
23

24 59 Symptoms alone do not allow for an accurate diagnosis of EIB, and standardized  
25  
26 60 objective tests are required[9–11]. The most common challenge/test conducted for detecting  
27  
28  
29 61 EIB in clinical practice is running on a treadmill or pedaling on a stationary bicycle. This  
30  
31 62 involves increasing the exercise intensity in the first 2 min to achieve a heart rate between  
32  
33  
34 63 80% and 90% of the predicted maximum, and maintaining this exercise intensity for another  
35  
36 64 4–6 min[5]. This protocol requires baseline and serial measurements of the forced expiratory  
37  
38  
39 65 volume in the first second (FEV<sub>1</sub>) for 30-min after the exercise. EIB diagnosis is established if  
40  
41 66 there is a reduction in the FEV<sub>1</sub> of  $\geq 10\%$  as compared to the baseline value at any moment  
42  
43  
44 67 after the challenge[5]. Some individuals may not be able to complete these challenges, or  
45  
46 68 achieving the target heart rates may be difficult in highly trained athletes[12].  
47

48 69 The main determinants of EIB are dehydration and thermal stress imposed on the  
49  
50  
51 70 airway epithelium due to high ventilation rates (VRs) achieved during moderate to intense  
52  
53  
54 71 exercise. This results in water loss and osmotic changes in the periciliary fluid of the  
55  
56 72 bronchial epithelium, resulting in the release of chemical mediators from the epithelial and  
57  
58 73 inflammatory cells and sensory nerve activation, which leads to bronchial constriction[5, 7].  
59  
60  
61  
62  
63  
64  
65

74 Surrogate tests for EIB diagnosis that do not require exercise and impose a similar  
1  
2 75 osmotic stress on the airway epithelium include eucapnic voluntary hyperpnoea (EVH) and  
3  
4 76 inhalation of saline hyperosmolar aerosols or dry powder mannitol[5]. EVH is the most  
5  
6  
7 77 studied method, is considered safe[13–15], and allows better control over ventilation and  
8  
9  
10 78 inspired air conditions[5]. In an EVH test, the patient hyperventilates for 6 min breathing in  
11  
12 79 dry air enriched with 5% CO<sub>2</sub> (to avoid alkalosis) at a recommended VR of 21 times the  
13  
14 80 individual's FEV<sub>1</sub> for non-athletes and 30 times the FEV<sub>1</sub> for athletes, corresponding to 60%  
15  
16  
17 81 and 85% of maximum voluntary ventilation (MVV), respectively[13,16].  
18

19 82 Most studies that evaluated the influence of VR in EVH tests for EIB diagnosis were  
20  
21  
22 83 performed in athletes[12,17,18]. In a study evaluating the utility of EVH in clinical settings,  
23  
24 84 the need for further investigations to explore the ventilatory stimulus threshold for EIB  
25  
26  
27 85 diagnosis became evident[14]. Therefore, the objective of this study was to verify whether  
28  
29 86 FEV<sub>1</sub> responses indicative of an EIB diagnosis are related to the VRs achieved during EVH  
30  
31  
32 87 test in children and adolescents with asthma. We hypothesized that the higher the VR  
33  
34 88 achieved, higher is the likelihood of a response indicating an EIB diagnosis.  
35

36 89

37  
38  
39 90  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 91 **Methods**

### 92 *Study design, period, and ethics*

93 This cross-sectional study was conducted at the Pulmonary Functional Laboratory of the  
94 Hospital das Clínicas at the Federal University of Pernambuco, Recife, Brazil between March  
95 and October 2019. It was approved by the institution's Ethics Committee (Agreement  
96 No.:2.796.049). All parents and adolescents signed an informed consent form, as requested by  
97 the Brazilian Regulatory Agency.

### 98 *Study population*

99 The study participants included children and adolescents of both sexes and aged 10–20  
100 years, having asthma. Participants who were diagnosed with asthma according to the Global  
101 Initiative for Asthma, 2018[19] were referred from the allergy and clinical immunology,  
102 pulmonology, and pediatric clinics of the same hospital to participate in the study. This  
103 hospital mainly serves the underprivileged population. **Patients were first-time incomers, were  
104 in the initial clinical evaluation process and still have not had treatment readjustments to  
105 achieve adequate control of symptoms.**

106 The exclusion criteria were as follows: baseline FEV<sub>1</sub><60% of the predicted value,  
107 inability to perform forced expiratory maneuvers adequately for FEV<sub>1</sub> determination,  
108 presence of other conditions precluding hyperpnea maneuvers required by the protocol,  
109 inability to suspend medication for the tests, use of systemic corticosteroids, or affirmative  
110 response to a question regarding the presence of respiratory infection symptoms in the 6  
111 weeks prior to the evaluation.

### 112 *Procedures*

113 The weight(kg) and height(cm) of the participants were measured on a calibrated scale  
114 and stadiometer, respectively (Welmy W 200, Santa Barbara d'Oeste, SP, Brazil). After  
115 anthropometric measurements patients responded to the Asthma Control Test(ACT)[20].

116 The EVH test followed a standardized protocol [5] and was performed in the morning.  
1  
2 117 Patients were instructed not to drink beverages with caffeine or perform vigorous exercise on  
3  
4 118 the testing day. The duration of suspension of the medications in use was as follows: inhaled  
5  
6  
7 119 short-acting beta-2 agonists, 12 h; inhaled long-acting beta-2 agonists, 48 h; and inhaled  
8  
9  
10 120 steroids, 24 h[5].

11  
12 121 The baseline FEV<sub>1</sub> was determined using a daily calibrated spirometer(microQuark,  
13  
14 122 COSMED, Rome, Italy) in accordance with international protocols[21]. The measurement  
15  
16  
17 123 was repeated in duplicate at 5, 15, and 30 min after EVH, and the best FEV<sub>1</sub> value was  
18  
19 124 selected for analysis. The predicted values were as proposed by Pereira et al.[22] for  
20  
21  
22 125 Brazilians.

23  
24 126 For EVH, the patients breathed a mixture of dry air and 5% CO<sub>2</sub>(White-Martins,  
25  
26 127 Recife, PE, Brazil) through their mouth using a one-way low-resistance valve(Laerdal,  
27  
28  
29 128 Copenhagen, Denmark) via a Douglas balloon reservoir with a nose clip worn throughout the  
30  
31  
32 129 procedure. The test lasted 6 min, and the patients were encouraged every 30 s to reach and  
33  
34 130 maintain a target VR 21 times that of their baseline FEV<sub>1</sub>. The VR was monitored using an  
35  
36 131 analogic ventilometer(Wright Mark 8 NSPIRE Health, Colorado, USA) and assessed at the  
37  
38  
39 132 end of each minute of the hyperpnea maneuver.

40  
41 133 A decrease of  $\geq 10\%$  in the FEV<sub>1</sub> as compared to the baseline value during any  
42  
43 134 measurement time point after the challenge(5, 15, or 30 min) was considered a positive  
44  
45  
46 135 response to the EVH challenge and an EIB-compatible diagnosis[5]. All negative responses  
47  
48  
49 136 were reevaluated within 48–72 h by following the same methodology and at the same hour of  
50  
51 137 the day as that of the first evaluation.

### 52 53 138 *Statistical analysis*

54  
55  
56 139 The data were processed and analyzed using the Statistical Package for the Social  
57  
58 140 Sciences(SPSS), version 20 and the figures were made by the GraphPad InStat program. The  
59  
60  
61  
62  
63  
64  
65

141 Shapiro–Wilk test was applied to assess normality. Values are expressed as frequencies(%),  
1  
2 142 means±standard deviations, or medians(25–75% percentile). Comparisons between the means  
3  
4  
5 143 were performed using the parametric student’s t-test, while that between the medians were  
6  
7 144 performed using the Mann–Whitney and **Kruskal-Wallis tests**. The chi-square test was used to  
8  
9  
10 145 assess differences between proportions. The Wilcoxon test was used to compare within-  
11  
12 146 subjects’ differences between different days. Spearman’s correlation was performed to assess  
13  
14 147 the relationship between the achieved VR as a multiple of the baseline FEV<sub>1</sub> and the  
15  
16  
17 148 maximum change in the FEV<sub>1</sub> expressed as a percentage change from the baseline after the  
18  
19 149 EVH challenge.

20  
21  
22 150 The achieved VRs were classified as follows: low( $\leq 17$  times the baseline FEV<sub>1</sub>),  
23  
24 151 intermediate( $>17$  and  $\leq 21$  times the baseline FEV<sub>1</sub>), and high( $>21$  times the baseline FEV<sub>1</sub>).

25  
26 152 All conclusions were based on a significance level of 5%.  
27  
28  
29 153  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 154 Results

1  
2 155 This study included 72 young asthma patients (33 boys and 39 girls), with a mean age  
3  
4  
5 156 of 14.52±3.45 years. None of them engaged in regular sports activities. A positive FEV<sub>1</sub>  
6  
7 157 response, i.e., decrease of ≥10% as compared to the baseline value, was noted in 36 patients  
8  
9  
10 158 (50%) after the first EVH challenge. The patients' baseline characteristics for the whole  
11  
12 159 sample and categorized according to the EVH challenge responses are shown in Table 1. As  
13  
14 160 shown, none of the variables, except for the FEV<sub>1</sub> response to the EVH, showed statistically  
15  
16  
17 161 significant differences between the categories.

18  
19 162 Overall, the median VR achieved was 46.03 L/min (interquartile range [IQR], 38.23–  
20  
21  
22 163 64.33), which represented a median of 19.28 times the baseline FEV<sub>1</sub> (IQR, 16.91–22.60).  
23  
24 164 The achieved VRs did not differ between individuals with and without a positive FEV<sub>1</sub>  
25  
26  
27 165 response to the EVH challenge, neither as a percentage of the calculated value nor as a  
28  
29 166 multiple of the baseline FEV<sub>1</sub> (Figure 1A and B). Additionally, there was no association  
30  
31  
32 167 between the number of individuals with a positive response and the categorized VR as a  
33  
34 168 multiple of the baseline FEV<sub>1</sub> (Table 2, top row).

35  
36 169 Moreover, no correlation was found between the maximum FEV<sub>1</sub> decrease after EVH  
37  
38  
39 170 and the achieved VR as a multiple of the baseline FEV<sub>1</sub> (Figure 2). **Even when categorizing**  
40  
41 171 **FEV1 responses in those individuals with a reduction <10%, > 10% < 25% and those > 25%**  
42  
43  
44 172 **there were no differences in ventilation rates between categories (Kruskal-Wallis test; p-value**  
45  
46 173 **= 0.888).**

47  
48  
49 174 On the day of the second EVH challenge conducted for those with a negative EIB-  
50  
51 175 compatible response (EIB-cr) in the first challenge (n=36), 14 showed a positive FEV<sub>1</sub>  
52  
53  
54 176 response compatible with EIB diagnosis. There were no differences in the baseline FEV<sub>1</sub> as a  
55  
56 177 percentage of the predicted values between those with and without a positive response  
57  
58 178 (median: 96.71% and 93.20% and IQR: 88.91–103.95% and 79.75–103.32%, respectively;  
59  
60  
61  
62  
63  
64  
65



179 p=0.997). Furthermore, in the second evaluation, no association was found between the  
1  
2 180 achieved VR categories and bronchial response to the EVH challenge (Table 2, bottom).

3  
4  
5 181  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 182 Discussion

1  
2  
3 183 We hypothesized that the higher the VR achieved in the EVH challenge, higher is the  
4  
5 184 likelihood of an EIB-cr of FEV<sub>1</sub>. However, our results found no association or correlation  
6  
7  
8 185 between these variables. Moreover, patients with VRs considered low (<17 times the baseline  
9  
10 186 FEV<sub>1</sub>) and those with rates considered high (>21 times the baseline FEV<sub>1</sub>) had a similar  
11  
12  
13 187 proportion of EIB-cr. Additionally, important variations in the achieved VRs were observed  
14  
15 188 even when the patients were encouraged every 30 s during the EVH challenge to attain the  
16  
17  
18 189 guideline target[5].

19  
20 190 EVH is considered a valid surrogate to exercise challenges for EIB diagnosis[5],  
21  
22 191 despite the fact that a recent meta-analysis found high agreement between the two challenges  
23  
24  
25 192 only among those individuals with negative results (using EVH as reference)[23]. Increased  
26  
27 193 VR together with the inhalation of dry air during the EVH challenge simulates the stimulus of  
28  
29  
30 194 high-intensity exercise and induces dehydration and osmotic changes in the periciliary fluid  
31  
32 195 layer of the bronchial mucosa[5]. This stimulates the epithelial and inflammatory cells and  
33  
34  
35 196 nerve fibers to release mediators capable of inducing a bronchospastic response[7]. For elite  
36  
37 197 athletes or those who train at high VRs on a daily basis, guidelines suggest a VR of 85% of  
38  
39  
40 198 the MVV(calculated as 30 times the baseline FEV<sub>1</sub>)[5] for an EVH challenge to be considered  
41  
42 199 adequate. For asthma patients, the adequate VR is required to be at least 17.5 times the  
43  
44  
45 200 baseline FEV<sub>1</sub> and preferably >21 times the FEV<sub>1</sub> for a test to be considered valid[5].

46  
47 201 Overall, we observed an EIB-cr in 69% of our patients: in 36 (50%) patients after the  
48  
49 202 first EVH challenge and in 14 (19%) patients after the challenge was repeated within 48–72 h  
50  
51  
52 203 for those without an EIB-cr in the first evaluation. A VR <17 times the baseline FEV<sub>1</sub>  
53  
54 204 (approximately 50% of the MVV) was achieved by 18 (25%) patients, and an EIB-cr was  
55  
56  
57 205 observed in 9 of them. In the second challenge repeated for the 36 individuals with a negative  
58  
59  
60  
61  
62  
63  
64  
65

206 response in the initial evaluation, this low VR was achieved by 8, of which 2 showed an EIB-  
1  
2 207 cr.  
3

4 208 Another study also reported a similar rate of positive response in FEV<sub>1</sub> after repeating  
5  
6  
7 209 the EVH challenge in individuals who initially presented negative responses[24]. Comparable  
8  
9  
10 210 results were observed in adult recreational athletes by Price et al.[18]. They reported a  
11  
12 211 positive response in the second EVH challenge in 19% of individuals who had a negative  
13  
14 212 response in the first challenge. They highlighted the need for caution when excluding an EIB  
15  
16  
17 213 diagnosis based on a single EVH test presenting a negative result. Anderson et al.[25] found  
18  
19 214 that 17% of their participants with a negative response in the first exercise test on a treadmill  
20  
21  
22 215 presented a positive response in the second one. Thus, excluding an EIB diagnosis based on a  
23  
24 216 single EVH or exercise test should be done so cautiously.  
25

26 217 Our study population comprised patients with an asthma diagnosis visiting a  
27  
28  
29 218 specialized clinical practice, i.e., a group in whom exercise-associated respiratory symptoms  
30  
31 219 are prevalent, and EIB must be correctly diagnosed in order to provide adequate treatment[1,  
32  
33  
34 220 8]. For the baseline characteristics that could interfere with bronchial response[5] to the EVH  
35  
36 221 test, no statistical differences were observed in the percentage of predicted baseline FEV<sub>1</sub> and  
37  
38  
39 222 asthma control evaluated by the ACT between individuals with and without an EIB-cr.  
40

41 223 Notably, there were no safety issues reported, and no test had to be interrupted due to  
42  
43  
44 224 respiratory symptoms or hemoglobin desaturation <94%; however, it is mandatory that the  
45  
46 225 test be conducted by trained personnel and that resources be available for a possible severe  
47  
48  
49 226 response. Our experience[11] and that of others[14,15,26,27] indicate that 60% of the  
50  
51 227 predicted FEV<sub>1</sub> value instead of 75%[5] is adequate as a safety cutoff point to conduct such  
52  
53 228 challenges/tests for EIB diagnosis.  
54

55 229 Minute ventilation, duration, and intensity of exercise are reported as the most  
56  
57  
58 230 important factors triggering EIB[5,7,13]. Although heart rate is used as a surrogate measure of  
59  
60  
61  
62  
63  
64  
65

231 the exercise intensity for diagnosing EIB, its relationship with VR varies widely based on  
1  
2 232 physical fitness and other factors[13,17,18,28,29]. Similar to the findings of other  
3  
4 233 authors[13,17,18,28–30], we observed an EIB-cr in many individuals who did not achieve the  
5  
6  
7 234 calculated target VR of 21 times the baseline FEV<sub>1</sub>.

9  
10 235 Brummel et al.[14] conducted a retrospective study on an older population that  
11  
12 236 included elite and non-elite athletes and an undefined number of individuals with asthma.  
13  
14 237 They reported that the proportion of EIB-cr in individuals not reaching the target VR of 21  
15  
16 238 times the baseline FEV<sub>1</sub> was significantly higher than that of individuals who achieved or  
17  
18  
19 239 surpassed the target VR (33% vs. 26%). In contrast to the findings of these authors, we cannot  
20  
21  
22 240 regard one negative test as sufficient to rule out an EIB diagnosis, based on the premise that  
23  
24 241 an achieved VR target of  $\geq 21$  times the baseline FEV<sub>1</sub> is a valid EVH challenge. In fact, 39%  
25  
26 242 of our patients with a negative response in the first test (14/36) showed a positive response in  
27  
28  
29 243 the second EVH challenge performed after 48–72 h, with an achieved VR below this target in  
30  
31 244 half of them.

33  
34 245 This study has some limitations. First, we did not evaluate the VR based on a  
35  
36 246 maximum effort test(i.e., VR 30 times the baseline FEV<sub>1</sub>), although the suggested VR target  
37  
38  
39 247 for asthma patients is 21 times the baseline FEV<sub>1</sub>[5]. Second, the method of measuring the  
40  
41 248 VR every minute using an analogical ventilometer instead of a continuous measurement may  
42  
43  
44 249 also have contributed to the number of individuals with a VR below the target. Third, our  
45  
46 250 established target of 21 times the baseline FEV<sub>1</sub> may have contributed to a low number of  
47  
48  
49 251 individuals reaching this target (35%), and aiming for a higher rate(i.e., 25 or 30 times the  
50  
51 252 baseline FEV<sub>1</sub>) could have increased the achieved VR. Nevertheless, the proportion of  
52  
53  
54 253 individuals with an EIB-cr in the EVH challenge was similar to the reported literature  
55  
56 254 prevalence of EIB among asthma patients(approximately 50%)[5].  
57  
58  
59  
60  
61  
62  
63  
64  
65

255 In conclusion, the achieved VRs in this study did not differ between individuals with  
1  
2 256 and without an EIB-cr in the EVH challenge. This indicates that VR is not the only  
3  
4 257 determinant of the bronchospastic response and that other non-recognized variables may  
5  
6  
7 258 influence this process. These findings emphasize the need for further investigations to assess  
8  
9  
10 259 if there is a minimum VR and to determine that VR. Furthermore, future studies should be  
11  
12 260 conducted to determine the necessary criteria to consider a test as effective and valid for EIB  
13  
14 261 diagnosis. Currently, it appears that the EVH challenge should be repeated at least once in  
15  
16  
17 262 individuals without an EIB-cr in the first evaluation to rule out EIB diagnosis. Irrespective of  
18  
19 263 the achieved VR, a positive FEV<sub>1</sub> response after EVH is suggestive of an EIB diagnosis and  
20  
21  
22 264 must be considered relevant for clinical and therapeutic assessments.  
23  
24  
25 265

26 266  
27  
28 **Conflict of Interest: None**  
29  
30  
31

32 267

33  
34  
35 268

36  
37  
38 269

39  
40  
41 270

42  
43  
44 271

45  
46  
47  
48 272

49  
50  
51 273

52  
53  
54  
55 274

56  
57  
58  
59  
60  
61  
62  
63  
64  
65

275 **References**

- 1  
2
- 3 276 1. Rabe KF, Adachi M, Lai CK., et al (2004) Worldwide severity and control of asthma in  
4  
5 277 children and adults: the global asthma insights and reality surveys. *J Allergy Clin*  
6  
7  
8 278 *Immunol* 114:40–47. <https://doi.org/10.1016/j.jaci.2004.04.042>  
9
- 10  
11 279 2. Mancuso CA, Sayles W, Robbins L, et al (2006) Barriers and Facilitators to Healthy  
12  
13 280 Physical Activity in Asthma Patients. *J Asthma* 43:137–143.  
14  
15  
16 281 <https://doi.org/10.1080/02770900500498584>  
17
- 18  
19 282 3. Velsor-Friedrich B, Vlasses F, Moberley J, Coover L (2004) Talking With Teens  
20  
21 283 About Asthma Management. *J Sch Nurs* 20:140–148.  
22  
23 284 <https://doi.org/10.1177/10598405040200030401>  
24  
25
- 26 285 4. Williams B, Powell A, Hoskins G, Neville R (2008) Exploring and explaining low  
27  
28  
29 286 participation in physical activity among children and young people with asthma: a  
30  
31 287 review. *BMC Fam Pr* 9:40. <https://doi.org/10.1186/1471-2296-9-40>  
32  
33
- 34 288 5. Parsons JP, Hallstrand TS, Mastronarde JG, et al (2013) An official American thoracic  
35  
36 289 society clinical practice guideline: Exercise-induced bronchoconstriction. *Am J Respir*  
37  
38  
39 290 *Crit Care Med* 187:1016-1027 online supplement.  
40  
41 291 <https://doi.org/10.1164/rccm.201303-0437ST>  
42  
43
- 44 292 6. Gotshall RW (2002) Exercise-Induced Bronchoconstriction. *Drugs* 62:1725–1739.  
45  
46 293 <https://doi.org/10.2165/00003495-200262120-00003>  
47  
48
- 49 294 7. Weiler JM, Anderson SD, Randolph C, et al (2010) Pathogenesis, prevalence,  
50  
51  
52 295 diagnosis, and management of exercise-induced bronchoconstriction: a practice  
53  
54 296 parameter. *Ann Allergy Asthma Immunol* 105:S1–S47.  
55  
56 297 <https://doi.org/10.1016/j.anai.2010.09.021>  
57  
58
- 59 298 8. Lang JE (2019) The impact of exercise on asthma. *Curr Opin Allergy Clin Immunol*  
60  
61  
62  
63  
64  
65

- 299 19:118–125. <https://doi.org/10.1097/ACI.0000000000000510>
- 1  
2  
3 300 9. Parsons JP, Kaeding C, Phillips G, et al (2007) Prevalence of Exercise-Induced  
4  
5 301 Bronchospasm in a Cohort of Varsity College Athletes. *Med Sci Sport Exerc* 39:1487–  
6  
7 302 1492. <https://doi.org/10.1249/mss.0b013e3180986e45>
- 8  
9  
10 303 10. Hallstrand TS, Curtis JR, Koepsell TD, et al (2002) Effectiveness of screening  
11  
12 304 examinations to detect unrecognized exercise-induced bronchoconstriction. *J Pediatr*  
13  
14 305 141:343–349. <https://doi.org/10.1067/mpd.2002.125729>
- 15  
16  
17  
18 306 11. Dantas FMNA, Correia MAV, Silva AR, et al (2014) Mothers impose physical activity  
19  
20 307 restrictions on their asthmatic children and adolescents: An analytical cross-sectional  
21  
22 308 study. *BMC Public Health* 14:1–7. <https://doi.org/10.1186/1471-2458-14-287>
- 23  
24  
25  
26 309 12. Parsons JP, Cosmar D, Phillips G, et al (2012) Screening for exercise-induced  
27  
28 310 bronchoconstriction in college athletes. *J Asthma* 49:153–157.  
29  
30  
31 311 <https://doi.org/10.3109/02770903.2011.652329>
- 32  
33  
34 312 13. Anderson SD, Argyros GJ, Magnussen H, Holzer K (2001) Provocation by eucapnic  
35  
36 313 voluntary hyperpnoea to identify exercise induced bronchoconstriction. *Br J Sport Med*  
37  
38 314 35:344–347. <https://doi.org/10.1136/bjism.35.5.344>
- 39  
40  
41 315 14. Brummel NE, Mastrorarde JG, Rittinger D, et al (2009) The clinical utility of eucapnic  
42  
43 316 voluntary hyperventilation testing for the diagnosis of exercise-induced bronchospasm.  
44  
45 317 *J Asthma* 46:683–686. <https://doi.org/10.1080/02770900902972178>
- 46  
47  
48  
49 318 15. Burman J, Elenius V, Lukkarinen H, et al (2020) Cut- off values to evaluate  
50  
51 319 exercise- induced asthma in eucapnic voluntary hyperventilation test for children. *Clin*  
52  
53 320 *Physiol Funct Imaging* 40:343–350. <https://doi.org/10.1111/cpf.12647>
- 54  
55  
56  
57 321 16. Hallstrand TS, Leuppi JD, Joos G, et al (2018) ERS technical standard on bronchial  
58  
59 322 challenge testing: pathophysiology and methodology of indirect airway challenge  
60  
61  
62  
63  
64  
65

- 323 testing. *Eur Respir J* 52:1801033. <https://doi.org/10.1183/13993003.01033-2018>
- 1  
2  
3 324 17. Hull JH, Ansley L, Price OJ, et al (2016) Eucapnic Voluntary Hyperpnea: Gold  
4  
5 325 Standard for Diagnosing Exercise-Induced Bronchoconstriction in Athletes? *Sport Med*  
6  
7 326 46:1083–1093. <https://doi.org/10.1007/s40279-016-0491-3>
- 8  
9  
10 327 18. Price OJ, Ansley L, Hull JH (2015) Diagnosing Exercise-Induced Bronchoconstriction  
11  
12 328 With Eucapnic Voluntary Hyperpnea: Is One Test Enough? *J Allergy Clin Immunol Pr*  
13  
14 329 3:243–249. <https://doi.org/10.1016/j.jaip.2014.10.012>
- 15  
16  
17  
18 330 19. GINA (2018) Global Initiative for Asthma (GINA). [Cited 2021 fev 11]. Available  
19  
20 331 from: <http://www.ginasthma.org>
- 21  
22  
23 332 20. Roxo JPF, Ponte EV, Ramos DCB, et al (2010) Validação do Teste de Controle da  
24  
25 333 Asma em português para uso no Brasil: validation for use in Brazil. *J Bras Pneumol*  
26  
27 334 36:159–166. <https://doi.org/10.1590/S1806-37132010000200002>
- 28  
29  
30  
31 335 21. Miller MR (2005) Standardisation of spirometry. *Eur Respir J* 26:319–338.  
32  
33 336 <https://doi.org/10.1183/09031936.05.00034805>
- 34  
35  
36 337 22. Pereira C (2002) Espirometria. *J Pneumol* 28:S1–S82
- 37  
38  
39 338 23. Iftikhar IH, Greer M, Jaiteh A (2019) A Meta-analysis of Diagnostic Test Agreement  
40  
41 339 Between Eucapnic Voluntary Hyperventilation and Cardiopulmonary Exercise Tests  
42  
43 340 for Exercise-Induced Bronchoconstriction. *Lung* 197:483–492.  
44  
45 341 <https://doi.org/10.1007/s00408-019-00233-4>
- 46  
47  
48  
49 342 24. Rizzo JÂ, Rodrigues Filho E de A, Gonçalves AV, et al (2021) Reproducibility of  
50  
51 343 eucapnic voluntary hyperpnoea for exercise- induced bronchoconstriction diagnosis in  
52  
53 344 asthmatic children and adolescents. *Pediatr Allergy Immunol* 00:1–9.  
54  
55 345 <https://doi.org/10.1111/pai.13610>
- 56  
57  
58  
59 346 25. Anderson SD, Pearlman DS, Rundell KW, et al (2010) Reproducibility of the airway  
60  
61  
62  
63  
64  
65



- 347 response to an exercise protocol standardized for intensity, duration, and inspired air  
1  
2 348 conditions, in subjects with symptoms suggestive of asthma. *Respir Res* 11:120.  
3  
4  
5 349 <https://doi.org/10.1186/1465-9921-11-120>  
6
- 7 350 26. Nicolai T, Mutius E V., Reitmeir P, Wjst M (1993) Reactivity to Cold-Air  
8  
9  
10 351 Hyperventilation in Normal and in Asthmatic Children in a Survey of 5,697  
11  
12 352 Schoolchildren in Southern Bavaria. *Am Rev Respir Dis* 147:565–572.  
13  
14  
15 353 <https://doi.org/10.1164/ajrccm/147.3.565>  
16
- 17 354 27. Argyros GJ, Roach JM, Hurwitz KM, et al (1996) Eucapnic Voluntary  
18  
19  
20 355 Hyperventilation as a Bronchoprovocation Technique. *Chest* 109:1520–1524.  
21  
22 356 <https://doi.org/10.1378/chest.109.6.1520>  
23  
24
- 25 357 28. Spiering BA, Judelson DA, Rundell KW (2004) An evaluation of standardizing target  
26  
27  
28 358 ventilation for eucapnic voluntary hyperventilation using FEV<sub>1</sub>. *J Asthma* 41:745–749.  
29  
30 359 <https://doi.org/10.1081/JAS-200028004>  
31  
32
- 33 360 29. Blackie SP, Fairbairn MS, McElvaney NG, et al (1991) Normal values and ranges for  
34  
35  
36 361 ventilation and breathing pattern at maximal exercise. *Chest* 100:136–142.  
37  
38 362 <https://doi.org/10.1378/chest.100.1.136>  
39  
40
- 41 363 30. Williams NC, Johnson MA, Hunter KA, Sharpe GR (2015) Reproducibility of the  
42  
43 364 bronchoconstrictive response to eucapnic voluntary hyperpnoea. *Resp Med* 109:1262–  
44  
45  
46 365 1267. <https://doi.org/10.1016/j.rmed.2015.08.006>  
47  
48

366

367

368

369 **Statements and Declarations**

370

371 **Funding:** The authors declare that no funds, grants, or other support were received during the  
372 preparation of this manuscript.

373 **Competing Interests:** The authors have no relevant financial or non-financial interests to  
374 disclose.

375 **Author Contributions:** Laienne Carla Barbosa de Barros Albuquerque, Claudio Gonsalves  
376 de Albuquerque and Edil Rodrigues Filho contributed to data collection, analysis, conception,  
377 and design. José Ângelo Rizzo, Décio Medeiros, Marcos Andre Moura dos Santos, Steve  
378 Hunter, Nadia Gaua and Marco Aurélio de Valois Correia Junior contributed to conception,  
379 design, and interpretation of the data, the drafting of the paper or revising it critically for  
380 intellectual content; and the final approval of the version to be published. All authors agree to  
381 be accountable for all aspects of the work related to its accuracy or integrity and all authors  
382 read and approved the final manuscript.

383 **Ethics approval:** This study was performed in line with the principles of the Declaration of  
384 Helsinki. Approval was granted by the Ethics Committee of University B (Date. 2019/No.:  
385 2.796.049).

386 **Consent to participate:** All parents and adolescents signed an informed consent form

387

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65**388 Figure legends**

**389 Figure 1.** Comparison of the achieved ventilation rates between individuals with and without  
positive responses on FEV<sub>1</sub> in the first eucapnic voluntary hyperpnea challenge. The achieved  
ventilation rates are expressed either as percentage of the calculated (A – Median;  
interquartile range: 94.26%; 76.40%–102.70% vs. 85.23%; 80.35%–106.4%), or as a multiple  
of baseline FEV<sub>1</sub> (B- Median; interquartile range: 19.79; 16.04–21.58 vs. 17.90; 16.87–  
22.35). (Mann–Whitney U-test). FEV<sub>1</sub> = forced expiratory volume in the first second.

**396 Figure 2.** Correlation between the maximum decrease in the FEV<sub>1</sub> after EVH and the  
achieved ventilation rate calculated as a multiple of the baseline FEV<sub>1</sub> value. Solid non-  
graduated horizontal line represents the limit of 10% reduction in the FEV<sub>1</sub> as compared to  
the baseline value. Intermittent vertical lines represent the limits of achieved ventilation rates  
as multiples of the baseline FEV<sub>1</sub>. (FEV<sub>1</sub> = forced expiratory volume in the first second).

403

1

2 404

3

4 405

5

6 406

7

8 407 **Table 1.** Characterization of the overall sample and according to FEV<sub>1</sub> responses after eucapnic  
 9 408 voluntary hyperventilation (EVH).

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42 409

43 410

44 411

45 412

46 413

47

48

49 414

50

51 415

52

53 416

54

55 417

56

57 418

58

59 419

60

61

62

63

64

65

Variables	ALL (n=72)	POSITIVE EVH RESPONSE (n=36)	NEGATIVE EVH RESPONSE (n=36)	p
<b>Sex</b>				
Male (%)	33 (45.8)	17 (47.2)	16 (44.4)	0.813*
Female (%)	39 (54.2)	19 (52.8)	20 (55.6)	
<b>Age</b> (Years $\pm$ SD)	14.52 $\pm$ 3.45	13.14 $\pm$ 2.59	12.89 $\pm$ 2.88	0.697**
<b>Height</b> (cm $\pm$ SD)	154.8 $\pm$ 10.52	155.0 $\pm$ 11.14	154.6 $\pm$ 10.33	0.885**
<b>Weight</b> (kg $\pm$ SD)	50.16 $\pm$ 12.89	52.27 $\pm$ 14.02	48.13 $\pm$ 11.65	0.287**
<b>FEV<sub>1</sub></b>				
Baseline (L.sec <sup>-1</sup> ) (Median and IQR)	2.29 (1.87-2.80)	2.19 (1.90-2.64)	2.46 (1.84-2.91)	0.295‡
% predicted (Median and IQR)	86.50 (76.23-96.75)	81.80 (73.63-95.50)	91.55 (91.55-101.60)	0.108 ‡
Maximum fall as % of basal (Median and IQR)	10.13 (22.50 - 4.60)	22.34 (16.75-39.23)	4.66 (2.47- 6.83)	<0.001 ‡
<b>ACT score n (%)</b>				
≤ 19	23 (32%)	15 (42%)	8 (22%)	0.077*
> 19	49 (68%)	21 (58%)	28 (78%)	

Values are expressed as frequency (%), mean  $\pm$  standard deviation and median (IQR). POSITIVE RESPONSE = individuals with a fall in FEV<sub>1</sub>  $\geq$  10% after eucapnic voluntary hyperventilation (EVH) compared to baseline. NEGATIVE RESPONSE = individuals with a FEV<sub>1</sub> fall <10% after EVH compared to baseline. FEV<sub>1</sub> = forced expiratory volume in the first second. IQR = interquartile range. ACT = Asthma control test. \* Chi-squared test, \*\*t-test, ‡ Mann Whitney test.

420

1

2 421

3

4 422 **Table 2.** Association between bronchial responses and ventilation rates achieved at the first EVH  
 5 423 challenge (A) and at the second challenge in those with a negative response to the first challenge (B).

6

7 424

8

9

---

A- Ventilation rates and bronchial response to the first EVH challenge (n = 72)

---

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

Chi-squared test for trend p-value = 0.878

---

30

31

32

33

34

B- Ventilation rates and bronchial response at the second EVH challenge of  
 individuals with a negative test on the first day. (n = 36)

---

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

425 Chi-squared test for trend p-value = 0.349

---

56

57

58

59

60

61

62

63

64

65

426 \*EIB-cr = Exercise-induced bronchospasm compatible response

427



